Acasti Pharma Cost of Goods Sold 2014-2024 | GRCE
Acasti Pharma cost of goods sold from 2014 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
Acasti Pharma Annual Cost of Goods Sold
(Millions of US $) |
| 2024 |
$ |
| 2023 |
$ |
| 2022 |
$ |
| 2021 |
$0 |
| 2020 |
$ |
| 2019 |
$ |
| 2018 |
$ |
| 2017 |
$ |
| 2016 |
$0 |
| 2015 |
$0 |
| 2015 |
$ |
| 2014 |
$0 |
| 2014 |
$ |
| 2013 |
$0 |
| 2013 |
$ |
Acasti Pharma Quarterly Cost of Goods Sold
(Millions of US $) |
| 2024-06-30 |
|
| 2024-03-31 |
|
| 2023-12-31 |
|
| 2023-09-30 |
|
| 2023-06-30 |
|
| 2023-03-31 |
|
| 2022-12-31 |
|
| 2022-09-30 |
|
| 2022-06-30 |
|
| 2022-03-31 |
|
| 2021-12-31 |
|
| 2021-09-30 |
|
| 2021-06-30 |
|
| 2021-03-31 |
$0 |
| 2020-12-31 |
$0 |
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2018-06-30 |
|
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
|
| 2017-02-28 |
|
| 2016-11-30 |
|
| 2016-08-31 |
|
| 2016-05-31 |
|
| 2016-03-31 |
|
| 2016-02-29 |
$0 |
| 2015-12-31 |
$0 |
| 2015-09-30 |
$0 |
| 2015-06-30 |
$0 |
| 2015-03-31 |
|
| 2014-12-31 |
$0 |
| 2014-09-30 |
$0 |
| 2014-06-30 |
$0 |
| 2014-03-31 |
|
| 2014-02-28 |
|
| 2013-12-31 |
$0 |
| 2013-09-30 |
$0 |
| 2013-06-30 |
$0 |
| 2013-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
